arrow
L

Lee-Jah Chang

AstraZeneca
H指数:14
被引数:1,964

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Safety, Pharmacokinetics, and Predicted Neutralizing Activity of the SARS-CoV-2 Monoclonal Antibody Sipavibart: Results from Little DIPPER and the SUPERNOVA Substudy

Sipavibart单克隆抗体的安全性、药代动力学及预测的中和活性:Little DIPPER和SUPERNOVA亚组研究的结果

2026-09-070
OAAI
Pharmacokinetic Comparability Assessment of Tixagevimab and Cilgavimab Developed for COVID-19 Prevention and Treatment Using Standard Exposure Metrics and Partial Area Under the Curve

基于标准暴露指标和部分曲线下面积评估用于COVID-19预防和治疗的Tixagevimab和Cilgavimab的药代动力学可比性分析

2026-03-310
OAAI
A SARS-CoV-2 variant‑adjusted threshold of protection model for monoclonal antibody pre-exposure prophylaxis against COVID-19

针对COVID-19的单克隆抗体暴露前预防的保护阈值模型(SARS-CoV-2变体调整)

2025-10-140
OAAI
Efficacy and safety of sipavibart for prevention of COVID-19 in individuals who are immunocompromised (SUPERNOVA): a randomised, controlled, double-blind, phase 3 trial

西帕韦伯特(sipavibart)预防免疫低下人群COVID-19的疗效与安全性(SUPERNOVA):一项随机、对照、双盲、III期试验

2025-02-010
PRE
AZD3152 neutralizes SARS-CoV-2 historical and contemporary variants and is protective in hamsters and well tolerated in adults
2024-06-261
PRE
Immunogenicity and safety of high-dose quadrivalent influenza vaccine in Japanese adults ≥65 years of age: a randomized controlled clinical trial

大剂量四价流感疫苗在 ≥ 65岁日本成人中的免疫原性和安全性: 一项随机对照临床试验

2019-11-1918
OAAI
A Randomized, Double-Blinded, Placebo-Controlled, Phase 1 Study of a Replication-Defective Herpes Simplex Virus (HSV) Type 2 Vaccine, HSV529, in Adults With or Without HSV Infection
2019-05-0657
OAAI
Protection against malaria at 1 year and immune correlates following PfSPZ vaccination (vol 22, pg 614, 2016)
2016-06-071
PREAI
Protection against malaria at 1 year and immune correlates following PfSPZ vaccination
2016-05-09288
PREAI
Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trial
LANCET
IF88.5
2014-12-01213
PREAI